Immunotherapies and targeted therapies in medical oncology

被引：3

作者：

Rousseau, Benoit ^{[1
]}

Champiat, Stephane ^{[1
]}

Loirat, Delphine ^{[1
]}

Arrondeau, Jennifer ^{[1
]}

Lemoine, Nathalie ^{[1
]}

Soria, Jean-Charles ^{[1
]}

机构：

[1] Univ Paris 11, DITEP, Dept Innovat Therapeut & Essais Precoces, F-94800 Villejuif, France

来源：

BULLETIN DU CANCER | 2014年 / 101卷 / 01期

关键词：

immunotherapy; molecular targeted therapy; drug therapy/combination; clinical trial/phase I; REGULATORY T-CELLS; IMMUNE-CHECKPOINTS; COLORECTAL-CANCER; TUMOR; MELANOMA; SAFETY; ACTIVATION; IPILIMUMAB; EXPRESSION; INDUCTION;

D O I：

10.1684/bdc.2013.1865

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New immunotherapies, also called "immune checkpoints", are promising and showed interesting antitumoral activities in particular in advanced setting of melanoma, clear cell renal cancer or non-small cell lung carcinoma. These treatments include ipilimumab, anti-PD-1 and anti-PD-L1. There is a strong rational for combination of immunotherapies and targeted therapies. This review is dedicated to expose the theorical issues and preclinical data of such combinations. This review examined the impact of immunotherapies on transduction pathways and modification of immunity related to targeted therapies. First clinical data form early drug development studies showed the difficulties observed with such combination and limitating toxicities. Finally, potential interesting combinations are overviewed with an emphasis on sequential treatments.

引用

页码：31 / 39

页数：9

共 24 条

[1] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[2] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

[3] PD-L1 regulates the development, maintenance, and function of induced regulatory T cells [J].

Francisco, Loise M. ;

Salinas, Victor H. ;

Brown, Keturah E. ;

Vanguri, Vijay K. ;

Freeman, Gordon J. ;

Kuchroo, Vijay K. ;

Sharpe, Arlene H. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (13) :3015-3029

[4] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma [J].

Hamid, Omid ;

Robert, Caroline ;

Daud, Adil ;

Hodi, F. Stephen ;

Hwu, Wen-Jen ;

Kefford, Richard ;

Wolchok, Jedd D. ;

Hersey, Peter ;

Joseph, Richard W. ;

Weber, Jeffrey S. ;

Dronca, Roxana ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Zarour, Hassane ;

Joshua, Anthony M. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Algazi, Alain ;

Mateus, Christine ;

Boasberg, Peter ;

Tumeh, Paul C. ;

Chmielowski, Bartosz ;

Ebbinghaus, Scot W. ;

Li, Xiaoyun Nicole ;

Kang, S. Peter ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :134-144

[5] SHP-1 phosphatase activity counteracts increased T cell receptor affinity [J].

Hebeisen, Michael ;

Baitsch, Lukas ;

Presotto, Danilo ;

Baumgaertner, Petra ;

Romero, Pedro ;

Michielin, Olivier ;

Speiser, Daniel E. ;

Rufer, Nathalie .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (03) :1044-1056

[6]

Hodi FS, 2010, NEW ENGL J MED, V363, P1290

[7] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[8] Immune-Checkpoints : the new anti-cancer immunotherapies [J].

Ileana, Ecaterina ;

Champiat, Stephane ;

Soria, Jean-Charles .

BULLETIN DU CANCER, 2013, 100 (06) :601-610

[9] The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition [J].

Jiang, Xiaofeng ;

Zhou, Jun ;

Giobbie-Hurder, Anita ;

Wargo, Jennifer ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2013, 19 (03) :598-609

[10] Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma [J].

Khalili, Jahan S. ;

Liu, Shujuan ;

Rodriguez-Cruz, Tania G. ;

Whittington, Mayra ;

Wardell, Seth ;

Liu, Chengwen ;

Zhang, Minying ;

Cooper, Zachary A. ;

Frederick, Dennie T. ;

Li, Yufeng ;

Zhang, Min ;

Joseph, Richard W. ;

Bernatchez, Chantale ;

Ekmekcioglu, Suhendan ;

Grimm, Elizabeth ;

Radvanyi, Laszlo G. ;

Davis, Richard E. ;

Davies, Michael A. ;

Wargo, Jennifer A. ;

Hwu, Patrick ;

Lizee, Gregory .

CLINICAL CANCER RESEARCH, 2012, 18 (19) :5329-5340

← 1 2 3 →